Battered by mixed PhIII data, Trevena axes R&D staff and hunkers down around lead pain drug
Eight months after Trevena {TRVN} was hammered over some mixed Phase III results for its new pain therapy, the biotech is slashing its research group and circling the wagons around its lead therapy in pursuit of a new drug approval from the FDA.
Twenty-one staffers largely from the research arm are being cut — 30% of its total workforce. And chief scientific officer Michael Lark is headed to the exit as well in mid-December.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.